Current version snapshot
Current · version 2: Selank↗↗
Related names recorded in this version: Selank acetate↗
A synthetic seven-amino-acid peptide that FDA lists among withdrawn compounding nominations with possible safety risks. FDA states that it lacks important information on its safety in people.↗↗
The canonical profile remains the primary reading view. Read the canonical profile.
We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed. 6
What this version reported
The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Reader guide in this version
Key takeaway
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), recorded in FDA’s substance registry and also known as TP-7.1,3 The only human study found in this review is a 2015 Russian study of 70 patients with anxiety disorders, in which selank was added to the tranquilizer phenazepam; its design and results can be checked only from its abstract.6 FDA lists selank acetate among compounding nominations that were withdrawn after FDA identified possible safety risks, and states that it lacks important information on its safety in people.3 No FDA approval is reported in the sources reviewed here, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,5
At a glance
- What it is
- A synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, according to FDA’s substance registry.1
- FDA status
- No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists selank acetate among withdrawn nominations with possible safety risks.3
- Human evidence
- One small Russian clinical study of selank added to phenazepam, reported in a Russian journal. FDA states that it lacks important information on selank’s safety in people.3,6
- Evidence strength
- Limited human data
What is selank?
Selank is a synthetic peptide of seven amino acids: threonine, lysine, proline, arginine, proline, glycine and proline. FDA’s substance registry records it as selank and TP 7.1
FDA’s compounding safety-risk page refers to it as selank acetate (TP-7).3
How is selank thought to work?
The authors of a 2017 rat study describe selank as an anxiety-reducing peptide whose action may resemble that of benzodiazepine drugs.2
That proposed mechanism comes from animal research; the FDA sources reviewed here do not describe how selank acts in people.2,3
What do human studies show?
A 2015 Russian study compared the tranquilizer phenazepam alone in 30 patients with phenazepam plus selank in 40 patients with anxiety-phobic, hypochondriac and somatoform disorders.6
The authors report that phenazepam took effect sooner on a depression and anxiety rating scale when selank was added, that side effects of phenazepam such as poor attention and memory, sedation and fatigue were reduced, and that quality of life improved.6
The study is small, tested selank only alongside phenazepam, and is reported in Russian; its abstract does not say how patients were assigned or whether they or the assessors knew which treatment they had.6
FDA states that it lacks important information regarding any safety issues raised by selank acetate given to humans.3
What the evidence base contains
- Small, short, or incompletely reported human study A 2015 Russian study of 70 patients with anxiety disorders comparing phenazepam alone (30 patients) with phenazepam plus selank (40 patients). The abstract does not describe how patients were assigned to the groups.6
- Animal or laboratory research A 2017 rat study reporting that selank reduced anxiety-like behaviour in a maze test, alone and combined with diazepam, under chronic mild stress.2
Evidence-strength label: Limited human data. How this label is assigned
Is selank FDA-approved?
None of the sources reviewed here reports an approval of selank by FDA.1,3
FDA’s compounding safety-risk page, current as of April 22, 2026, lists selank acetate among bulk drug substances that were in category 2 before their nominations were withdrawn, citing possible immune reactions from aggregation and impurities.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Selank is not among them.4,5
What is still unknown?
Whether selank on its own is effective for anxiety: the human study reviewed here added it to phenazepam, and its methods can be checked only from the abstract.6
Whether it is safe in people: FDA states that it lacks important safety information.3
Whether effects seen in rats would carry over to people.2
Sources for this version
- 1Selank substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 2Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (2017) · PMID 28280289 ↗
Behavioural Neurology · Official source · Source checked November 15, 2026
- 3Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 5HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6Optimization of the treatment of anxiety disorders with selank (2015, in Russian) · PMID 26356395 ↗
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Official source · Source checked November 16, 2026